These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 7232966)

  • 21. [Bromocriptin in the treatment of progressive stages of Parkinson's disease (author's transl)].
    Schneider E; Fischer PA
    Dtsch Med Wochenschr; 1982 Feb; 107(5):175-9. PubMed ID: 6799266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa.
    Wallis WE
    Eur Neurol; 1988; 28 Suppl 1():9-10. PubMed ID: 3288479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
    Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
    Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early combination therapy with bromocriptine and levodopa in Parkinson's disease.
    Factor SA; Weiner WJ
    Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
    Todman DH; Oliver WA; Edwards RL
    Clin Exp Neurol; 1990; 27():79-82. PubMed ID: 2129961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 29. [Combined therapy of parkinsonism with bromocriptine, L-dopa and decarboxylase inhibitor (author's transl)].
    Vardy J; Rabey JM; Streifler M
    Harefuah; 1977 Sep; 93(5-6):129-33. PubMed ID: 924233
    [No Abstract]   [Full Text] [Related]  

  • 30. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 31. Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease.
    Vogel HP; Schiffter R
    Pharmacopsychiatria; 1983 Jul; 16(4):107-10. PubMed ID: 6685318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease.
    Uchiyama T; Sakakibara R; Yamamoto T; Ito T; Yamaguchi C; Awa Y; Yano M; Yanagisawa M; Kobayashi M; Higuchi Y; Ichikawa T; Yamanishi T; Hattori T; Kuwabara S
    Mov Disord; 2009 Dec; 24(16):2386-90. PubMed ID: 19908315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bromocriptine in Parkinson's disease: a study of cardiovascular effects.
    Quinn N; Illas A; Lhermitte F; Agid Y
    J Neurol Neurosurg Psychiatry; 1981 May; 44(5):426-9. PubMed ID: 7264689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [How do we explain the antihypertensive effect of bromocriptine? Clinical and experimental contribution].
    Chamontin B; Montastruc JL; Rascol A
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1181-5. PubMed ID: 6151826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
    Pezzoli G; Martignoni E; Pacchetti C; Angeleri VA; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
    Mov Disord; 1994 Jul; 9(4):431-6. PubMed ID: 7969210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease.
    Stern GM; Lees AJ
    Adv Neurol; 1983; 37():17-21. PubMed ID: 6858771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.